


2nd International Electronic Conference on Medicinal Chemistry

1-30 November 2016 chaired by Dr. Jean Jacques Vanden Eynde



Antibacterial activity of zinc(II) and copper(II) terpyridine complexes


Tanja Soldatović^{1,*}, Enisa Selimović¹, and Braho Ličina²

- ¹ Department of Chemical-Technological Science, State University of Novi Pazar, Vuka Karadžiča bb, 36300 Novi Pazar, Serbia;
- ² Department of Biomedical Science, State University of Novi Pazar, Novi Pazar, Vuka Karadžiča bb, 36300 Novi Pazar, Serbia.

* Corresponding author: tsoldatovic@np.ac.rs



Antibacterial activity of zinc(II) and copper(II) terpyridine complexes





2nd International Electronic Conference on Medicinal Chemistry 1-30 November 2016





pharmaceuticals

Abstract:

Zinc(II) and copper(II) complexes with organic molecules are used in clinical medicine, e.g. (i) complex of zinc(II) acetate with erythromycin is used for ache therapy, (ii) copper chelating agents were developed to treat Wilson disease, an autosomal recessive genetic disorder that causes copper accumulation primarily in the liver. In general, organic ligands can contribute to better transport of metal ions through the lipophillic regions of cell membranes. However, it is also possible that some metal complexes are not able to reach their site of action in sufficient concentration due to their decreased solubility. Antibacterial activity of model [ZnCl2(terpy)] and [CuCl2(terpy)] complexes was tested against seven strains of bacteria. The complexes were more effective against Gram-positive than Gram-negative bacteria. Between complexes, stronger effect was observed for [CuCl2(terpy)] complex. The best effect was exhibited against Sarcina lutea (5) mg/ml). Escherichia coli showed low sensitivity to both complexes. Results of the study of the antibacterial activity suggest an absence of permeability of the complexes through the membrane proteins.

Keywords: Zinc(II); Copper(II); Biomolecules; Antibacterial activity



2nd International Electronic Conference on Medicinal Chemistry 1-30 November 2016




Introduction

Zinc(II) and copper(II) complexes with organic molecules are used in clinical medicine, e.g. complex of zinc(II) acetate with erythromycin is used for ache therapy [1]. Copper chelating agents were developed to treat Wilson disease, an autosomal recessive genetic disorder that causes copper accumulation primarily in the liver. The same agents were investigated for their capacity to control angiogenesis and to impair cancer growth and metastasis [2]. In general, biomolecules can contribute to better transport of metal ions through the lipophillic regions of cell membranes [3]. Our focus is to investigate the interaction between zinc and copper and bio-ligands in proteins environment. We are also interested in studies related to the biological activity and medical applications of model Zn(II) and Cu(II) complexes structurally similar to catalytic centres in metalloenzymes.



sponsors:





Results and discussion

Antibacterial activity

Antibacterial activity of $[ZnCl_2(terpy)]$ and $[CuCl_2(terpy)]$ complexes was tested against seven strains of bacteria. The results are presented in Table 1. The complexes were more effective against Gram-positive than Gram-negative bacteria.



2nd International Electronic Conference on Medicinal Chemistry 1-30 November 2016







Bacteria	[ZnCl ₂ (terpy)]		[CuCl ₂ (terpy)]	
	MIC ^a	MBC ^b	MIC	MBC
Bacillus subtilis	10	>20	10	10
Bacillus subtilis ATCC 6633	>20	20	5	10
Staphylococcus aureus	>20	>20	>	>20
Staphylococcus aureus	10	20	10	20
ATCC 25923				
Sarcina lutea	5	>20	1.25	5
Escherichia coli	10	>20	>	>20
Escherichia coli ATCC	10	>20	10	>20
25922				

Tabele 1. Antibacterial activity of [ZnCl₂(terpy)] and [CuCl₂(terpy)] complexes

^a Minimal inhibitory concentration (MIC).

^b Minimum bactericidal concentration (MBC) values are given as mg/ml.





The most active complexe was [CuCl₂(terpy)] complex (Table 1). The best effect was exhibited against *Sarcina lutea* (5 mg/ml). *Escherichia coli* showed low sensitivity to both complexes. The study of the antibacterial activity suggests an absence of permeability of the complexes through the membrane proteins.

Similar studies have shown that two new synthesized Cu(II) and Zn(II) complexes with xylitol have antibacterial effect against *P. aeruginosa* and *C. albicans*. Both copper and zinc complexes presented higher MIC against *P. aeruginosa* than the free xylitol, showing that these complexes could be better local antibacterial compounds than xylitol [4]. The square-pyramidal [Cu(Imx)(phen)(NO₃)]·5H₂O has shown minimum inhibitory concentration (MIC) in various *E. coli* strains and comparison with free lomefloxacin indicated that the Cu(II) complex is an antimicrobial agent that is as efficient as the free antibiotic but strongly suggested that the cell intake route of both species is different [5].







Conclusions

In conclusion, this study demonstrated stronger antibacterial activity of $[CuCl_2(terpy)]$ than $[ZnCl_2(terpy)]$. This can be in correlation with a stronger affinity of Cu(II) for biomolecules. Absence of permeability of the proteins through cell membrane is probably due to the low thermodynamic stability of the prepared complexes and their dissociation in the solution.



1st International Electronic Conference on Medicinal Chemistry 2-27 November 2015



Acknowledgments

The authors gratefully acknowledge financial support from State University of Novi Pazar, Novi Pazar, Republic Serbia and T. Soldatović also gratefully acknowledges financial support from Ministry of Education, Science and Technological Development, Republic of Serbia (Project No. 172011)

Reference

 C. L. Feucht, B. S. Allen, D. K. Chalker, J. Am. Acad. Dermatol., 3(1980) 483.
European Association for Study of Liver, J. Hepatol. 56 (2012) 671.
R. B. Martin" in Metal lons in Biological Systems, Vol. 20, H. Sigel, Ed. Marcel Dekker, New York and Basel, 1986.
Santi, C. Fasching, B. Fascia, P. P. Parrasa, A. J. Casta, Filha, C. Darthagaray, M.

[4] E. Santi, G. Facchina, R. Faccio, R.P. Barroso, A.J. Costa-Filho, G. Borthagaray, M. H. Torre, J. Inorg. Biochem. 155 (2016) 67.

[5] P. Fernandes, I. Sousa, L. Cunha-Silva, M. Ferrerira, B. de Castro, E.F. Pereira, M.J. Feio, P. Gameiro, J. Inorg. Biochem. 131 (2014) 21.





pharmaceuticals